(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US-11725004-B2 · Aug 15, 2023 · US
(cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US12344601B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12344601-B2 |
| Application number | US-202318216669-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 30, 2023 |
| Priority date | May 17, 2013 |
| Publication date | Jul 1, 2025 |
| Grant date | Jul 1, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating pain selected from the group consisting of acute pain, visceral pain, and neuropathic pain, comprising administering to a human being an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of and a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier, to treat the pain. 2. The method of claim 1 , wherein the compound is 3. The method of claim 1 , wherein the pain is acute pain. 4. The method of claim 2 , wherein the pain is acute pain. 5. The method of claim 3 , wherein the acute pain is trigeminal neuralgia. 6. The method of claim 4 , wherein the acute pain is trigeminal neuralgia. 7. The method of claim 1 , wherein the pain is visceral pain. 8. The method of claim 2 , wherein the pain is visceral pain. 9. The method of claim 1 , wherein the pain is neuropathic pain. 10. The method of claim 2 , wherein the pain is neuropathic pain. 11. The method of claim 9 , wherein the neuropathic pain is post-herpetic neuralgia. 12. The method of claim 10 , wherein the neuropathic pain is post-herpetic neuralgia. 13. The method of claim 9 , wherein the neuropathic pain is due to chemotherapy caused nerve injury. 14. The method of claim 10 , wherein the neuropathic pain is due to chemotherapy caused nerve injury. 15. The method of claim 9 , wherein the neuropathic pain is due to central nervous system injury. 16. The method of claim 10 , wherein the neuropathic pain is due to central nervous system injury. 17. The method of claim 9 , wherein the neuropathic pain is due to diabetic neuropathy. 18. The method of claim 10 , wherein the neuropathic pain is due to diabetic neuropathy. 19. The method of claim 9 , wherein the neuropathic pain is due to diabetic peripheral neuropathy. 20. The method of claim 10 , wherein the neuropathic pain is due to diabetic peripheral neuropathy.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
having one double bond between ring members or between a ring member and a non-ring member · CPC title
containing two hetero rings · CPC title
containing three or more hetero rings · CPC title
Nitrogen atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12344601B2 cover?
- This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
- Who is the assignee on this patent?
- Centrexion Therapeutics Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D417/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).